Glucose tolerance, insulin secretion and insulin sensitivity in polycystic ovary syndrome

Journal of the Pancreas

Volumn 3, Issue 1, 2002, Pages 1-7

  Pasquali, Renato ^a   Pelusi, Carla ^a   Ragazzini, Cecilia ^a   Hasanaj, Roana ^a   Gambineri, Alessandra ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Glucose intolerance; Hyperinsulinemia; Insulin (secretion); Polycystic ovary syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ESTRADIOL; INOSITOL DERIVATIVE; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; TROGLITAZONE; ANTIDIABETIC AGENT; INSULIN;

CLINICAL TRIAL; DRUG MECHANISM; DRUG RESEARCH; EDITORIAL; EXERCISE; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; WEIGHT REDUCTION; BLOOD; FEMALE; GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION;

FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME;

EID: 0036359613     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (47)

1. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50:113-6. [AN 80072366]
2. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29:181-91.
3. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In:Dunaif A, ed. Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1995: 377-84.
4. Pasquali R, Venturoli S, Paradisi R, Capelli M, Parenti N, Melchionda N. Insulin and C-peptide levels in obese patients with polycystic ovaries. Horm Metab Res 1982; 14:284-7. [AN 83005355]
5. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57:356-9. [AN 83238856]
6. Dahlgren E, Johansoon S, Lindstedt G, Kautsson F, Oden A, Jonson PO, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow up focusing on natural history and circulating hormones. Fertil Steril 1992; 57:505-13. [AN 92155373]
7. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weiner K, kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Tromb Vasc Biol 1995; 15:821-6. [AN 95323476]
8. Dunaif A. Insulin resistance and polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr Rev 1997; 18:774-800. [AN 98073041]
9. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333:853-61. [AN 95379908]
10. Holte J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Bailliers Clin Endocrinol Metab 1996; 10:221-47. [AN 96369806]
11. Dunaif A, Segal KR, Futterweit W, Dobrjiansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38:1165. [AN 89357286]
12. Dunaif A, Sorbara L, Delson R, Green G. Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women. Diabetes 1993; 42:1462-8. [AN 93387584]
13. Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotropins and sex steroids in premenopausal women. Clin Endocrinol (Oxf) 1994; 41:473-81. [AN 95043472]
14. Morin-Papunen LC, Vauhkomen I, Koivumen RM, Rouokomen A, Tapanaimen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovary syndrome. Hum Reprod 2000; 15:1266-74. [AN 20293223]
15. Morales AJ, Laughlin GA, Batzow T, Maheshwari H, Baumann G, Yen SC. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996; 81:2854-64. [AN 96320072]
16. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:942-7. [AN 96368547]
17. Micic D, Macut DJ, Popovic V, Sumarac-Dumanovic M, Kendereski A, Colic M, et al. Leptin levels and insulin sesitivity in obese and non-obese patients with polycystic ovary syndrome. Gynecol Endocrinol 1997; 11:315-20. [AN 98046640]
18. Grulet H, Heeart AC, Delemer B, Gross A, Sulmont V, Leutenegger M, Caron J. Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome. Clin Endocrinol (Oxf) 1993; 38:621-6. [AN 93327478]
19. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20 :535-82. [AN 99382729]
20. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes 1996; 20:291-302. [AN 96289739]
21. Holmong A, Svedberg J, Jennische E, Bjorntorp P. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol 1990; 259:E555-60. [AN 91023043]
22. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991; 14:1132-43. [AN 92128236]
23. Diamanti-Kandarakis E, Mitrakou A, Hennes MMI, Platanissiotis D, Kablas N, Spina J, et al. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 1995; 44:525-31. [AN 95240459]
24. Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996; 81:952-60. [AN 96368549]
25. Holte J, Bergh T, Berne C, Berglund L and Lithell H. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystiv ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 1994; 78:1052-8. [AN 94230665]
26. Ciampelli M, Fulgheus AM, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 1999; 48:167-72. [AN 99146681]
27. Ciampelli M, Fulgheus AM, Cucinelli F, Pavone V, Caruso A, Mancuso S, Lanzone A. Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 1997; 12:1897-901. [AN 98028332]
28. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistenly increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80:2586-93. [AN 95403640]
29. Swenne I. Pancreatic beta-cell growth and diabetes mellitus. Diabetologia 1992; 35:193-201. [AN 92225255]
30. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-23. [AN 79253316]
31. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Roseinfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non insulin diabetes mellitus. J Clin Invest 1995; 96:520-7. [AN 95340863]
32. Dunaif A. Hyperandrogenic anovulation (PCOS): A unique disorder of insulin action associated with an increased risk of non-insulin dependent diabetes mellitus. Am J Med 1995; 98(Suppl. 1A):33S-9. [AN 95126177]
33. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictions of the risk of type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84:165-9. [AN 99116805]
34. Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the long-term effect oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999; 50:517-27. [AN 99404962]
35. Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 2001; 86:2027-31. [AN 21242787]
36. Lanzone A, Caruso A, Di Simone N, DeCarolis S, Fulgheus AM, Mancuso S. Polycystic ovary disease. A risk for gestational diabetes?. J Reprod Med 1995:40:312-6. [AN 95349054]
37. Koivunen RM, Juutinen J, Vauhkonen I, Morin-Papunen LC, Ruokonen A, Tapanainen JS. Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes. J Clin Endocrinol Metab 2001; 86:2591-9. [AN 21291023]
38. Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol (Oxf) 1993; 39:1-16. [AN 93351329]
39. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36:105-11. [AN 92217207]
40. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, et al. Effect of long term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystyc ovary syndrome. J Clin Endocrinol Metab 2000; 85:2767-74. [AN 20401703]
41. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43:647-54. [AN 94231979]
42. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617-23. [AN 96320489]
43. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin sensitising agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299-306. [AN 96378524]
44. Ehrmann DA, Scheneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2108-16. [AN 97358160]
45. Korytkowski MT, Mokan M, Horwitz MJ, Berga SL. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80:3327-34. [AN 96064802]
46. Armstrong VL, Wiggam MI, Ennis CN, Sheridan B, Traub AI, Atkinson AB, Bell PM. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate. QJM 2001; 94:31-7. [AN 21109580]
47. Gonzalez C, Alonso A, Gruseo NA, Diaz F, Esteban MM, Fernandez S, Patterson AM. Effect of treatment with different doses of 17-beta estradiol on insulin receptor substrate-1. JOP. J. Pancreas (Online) 2001; 2:140-9.